EHA 2022 | The management of R/R FLT3-mutated AML
Shai Shimony
• 13 Jun 2022
Shai Shimony, MD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the management of relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML). Dr Shimony first highlights the promise of targeted therapies that have emerged in recent years, and then goes on to discuss various approaches to treating patients with R/R disease, including the role of transplant, maintenance therapy, and the importance of achieving measurable residual disease (MRD) negative responses. To conclude, Dr Shimony highlights promising combination therapies being evaluated. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
